A Secondary Analysis of DANFLU-1 Trial - High vs Standard Dose Influenza Vaccine in CKD | ESC 2024

Khurram Nasir, an Associate Editor at JACC with expertise in cardiovascular care, joins Tor Biering-Sorenson, a medical doctor with advanced public health degrees, to delve into the critical role of influenza vaccines for chronic kidney disease (CKD) patients. They discuss findings from the DANFLU-1 trial, highlighting the potential benefits of high-dose vaccines over standard doses. The conversation underscores the broader health impacts of flu vaccination, particularly in reducing complications in high-risk populations and advocating for increased immunization efforts in underserved communities.